BidaskClub upgraded shares of Tabula Rasa HealthCare (NASDAQ:TRHC) from a hold rating to a buy rating in a report published on Thursday morning.

TRHC has been the topic of several other research reports. First Analysis started coverage on Tabula Rasa HealthCare in a research note on Wednesday, November 1st. They set an overweight rating and a $41.00 price target on the stock. Piper Jaffray Companies reiterated an overweight rating and set a $35.00 price target on shares of Tabula Rasa HealthCare in a research note on Tuesday, November 7th. They noted that the move was a valuation call. Zacks Investment Research upgraded Tabula Rasa HealthCare from a hold rating to a strong-buy rating and set a $31.00 price target on the stock in a research note on Wednesday, October 11th. Wells Fargo & Co boosted their price target on Tabula Rasa HealthCare from $21.00 to $27.00 and gave the company a market perform rating in a research note on Thursday, October 19th. Finally, William Blair started coverage on Tabula Rasa HealthCare in a research note on Monday, December 11th. They set an outperform rating on the stock. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $29.00.

Tabula Rasa HealthCare (NASDAQ TRHC) opened at $29.39 on Thursday. The company has a market capitalization of $531.90, a price-to-earnings ratio of -117.56, a PEG ratio of 25.09 and a beta of 2.81. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.73 and a quick ratio of 0.66. Tabula Rasa HealthCare has a 1 year low of $11.59 and a 1 year high of $36.80.

Tabula Rasa HealthCare (NASDAQ:TRHC) last announced its earnings results on Monday, November 6th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.02. Tabula Rasa HealthCare had a negative return on equity of 5.58% and a negative net margin of 2.27%. The company had revenue of $33.27 million for the quarter, compared to analyst estimates of $31.76 million. During the same period in the prior year, the company posted $0.06 EPS. The firm’s quarterly revenue was up 37.6% compared to the same quarter last year. research analysts anticipate that Tabula Rasa HealthCare will post 0.05 earnings per share for the current year.

In related news, major shareholder Growth Fund 1Q Lp Originate sold 684,180 shares of the stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $25.85, for a total value of $17,686,053.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bruce Luehrs sold 269,000 shares of the stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $25.85, for a total value of $6,953,650.00. The disclosure for this sale can be found here. Insiders have sold 1,099,180 shares of company stock valued at $28,435,203 in the last three months. Insiders own 45.80% of the company’s stock.

Several large investors have recently bought and sold shares of the stock. California Public Employees Retirement System acquired a new stake in shares of Tabula Rasa HealthCare in the third quarter valued at approximately $254,000. Allianz Asset Management GmbH acquired a new stake in shares of Tabula Rasa HealthCare in the third quarter valued at approximately $3,801,000. Pier Capital LLC acquired a new stake in Tabula Rasa HealthCare during the third quarter worth $4,151,000. Schwab Charles Investment Management Inc. increased its stake in Tabula Rasa HealthCare by 69.4% during the third quarter. Schwab Charles Investment Management Inc. now owns 18,300 shares of the company’s stock worth $490,000 after acquiring an additional 7,500 shares during the last quarter. Finally, Wells Fargo & Company MN increased its stake in Tabula Rasa HealthCare by 79.8% during the third quarter. Wells Fargo & Company MN now owns 12,768 shares of the company’s stock worth $341,000 after acquiring an additional 5,668 shares during the last quarter. 31.85% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This story was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://theolympiareport.com/2017/12/24/tabula-rasa-healthcare-trhc-upgraded-at-bidaskclub.html.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.